AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Monday, September 25, 2023, 7:00
- Finance
- Add a comment
TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy Conditional marketing authorization approval from the European…
About the Author
adminasapcorp has written 39023 stories on this site.